Savara Inc Net Change in Cash
Savara Inc (SVRA) reported Net Change in Cash of $8.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-11
- Savara Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $5.61M, a 26.72% increase year-over-year.
- Savara Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $4.43M.
- Savara Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$9.80M.
- Savara Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$18.12M, a 140.07% decline year-over-year.
- Savara Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $18.05M.
- Savara Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$11.46M.
- Savara Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$25.52M, a 241.06% decline from fiscal 2022.
- Savara Inc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $18.09M, a 62.49% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.62M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $5.61M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $18.05M 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $1.15M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $2.31M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | $4.43M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$11.46M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | -$5.16M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | -$2.72M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | -$9.80M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | -$25.52M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$24.41M 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$29.36M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | -$18.12M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $18.09M 10-K · filed 2024-03-07 | |||
| 2022-09-30 | $85.83M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $61.14M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $45.22M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $11.13M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $21.82M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $17.77M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $33.10M 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | -$26.92M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | -$14.59M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | -$2.69M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$15.29M 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $25.50M 10-K · filed 2021-03-10 | |||
| 2019-09-30 | -$6.52M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | -$7.47M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $1.37M 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $2.18M 10-K · filed 2020-03-12 | |||
| 2018-09-30 | $2.83M 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $1.48M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $1.00K 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $8.75M 10-K · filed 2019-03-13 | |||
| 2017-09-30 | $6.44M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |